Maдопар (Benserazide, Levodopa)

Levodopa, one of the active ingredients, is a precursor of dopamine that crosses the blood‑brain barrier. Once inside the brain, it is converted to dopamine, restoring the neurotransmitter balance that is deficient in Parkinsonian disorders.

The dosage of Maдопар is individualized by the prescribing clinician based on disease severity, patient response, and tolerability. The prescriber determines the appropriate strength, frequency, and titration schedule for each patient.

Safety of Maдопар in pregnancy or lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Maдопар combines levodopa with benserazide, offering higher central availability of levodopa compared with levodopa alone. This combination often provides more consistent symptom control than monotherapy, though individual response varies and side‑effect profiles must be considered.

Maдопар tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Protect them from moisture, excessive heat, and direct light to maintain potency throughout the shelf life.

Maдопар is taken orally, usually with a glass of water. It may be taken with or without food, but high‑protein meals can affect absorption, so patients are often advised to separate dosing from protein‑rich meals.

Serious risks include dyskinesia (involuntary movements), severe hypotension, psychiatric disturbances such as hallucinations, and rare events like neuroleptic malignant syndrome. Patients should be monitored closely for these adverse reactions.

Maдопар is contraindicated in patients with narrow‑angle glaucoma, known hypersensitivity to levodopa or benserazide, and those taking non‑selective MAO inhibitors. It should also be used with caution in individuals with severe cardiovascular disease.